Go Pro
NASDAQ:FBIO

Fortress Biotech Q4 2025 Earnings Report

Fortress Biotech logo
$2.03 -0.04 (-1.93%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$2.05 +0.02 (+0.94%)
As of 10/2/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fortress Biotech EPS Results

Actual EPS
-$0.21
Consensus EPS
$0.11
Beat/Miss
Missed by -$0.32
One Year Ago EPS
N/A

Fortress Biotech Revenue Results

Actual Revenue
$16.08 million
Expected Revenue
$26.17 million
Beat/Miss
Missed by -$10.09 million
YoY Revenue Growth
N/A

Fortress Biotech Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
Monday, April 6, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Fortress Biotech's Q3 2026 earnings is estimated for Monday, November 16, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 11, 2026 at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Fortress Biotech Earnings Headlines

Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript
See More Fortress Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fortress Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fortress Biotech and other key companies, straight to your email.

About Fortress Biotech

Fortress Biotech (NASDAQ:FBIO) is a biopharmaceutical company focused on developing and commercializing medicines for serious and underserved medical conditions. The company operates through a network of subsidiaries and strategic partners, supporting drug discovery, clinical development, regulatory activities and commercialization.

Its research and development activities span areas including oncology, immunology, dermatology, central nervous system disorders and rare diseases. Fortress has used its platform to establish or support subsidiary companies developing therapeutic candidates and commercial products, with programs ranging from early-stage research through late-stage clinical development and marketed medicines.

Founded in 2014, Fortress Biotech serves patients primarily through the United States healthcare market while pursuing opportunities to advance its therapies internationally through licensing and commercial partnerships. Its business model emphasizes building specialized biotechnology companies around individual drug-development programs and therapeutic areas.

View Fortress Biotech Profile